0
Editorials: Point and Counterpoint |

Rebuttal From Drs Coz Yataco, Flannery, and Simpson

Angel O. Coz Yataco, MD, FCCP; Alexander H. Flannery, PharmD, BCPS; Steven Q. Simpson, MD, FCCP
Author and Funding Information

FINANCIAL/NONFINANCIAL DISCLOSURES: None declared.

CORRESPONDENCE TO: Angel O. Coz Yataco, MD, FCCP, University of Kentucky, KY Clinic, 740 S Limestone L-543, Lexington, KY 40536


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(6):1371-1372. doi:10.1016/j.chest.2016.03.051
Text Size: A A A
Published online

Extract

We agree with Dr Caironi that hypoalbuminemia, epiphenomenon or not, is associated with increased morbidity and mortality in critically ill patients. However, no study has shown that correcting hypoalbuminemia or using albumin in resuscitation alters these outcomes.

In the spirit of accepting our opponent’s challenge to debate the theory rather than the details of trial results, we keep our statistical concerns brief, as they have been outlined elsewhere. We agree that shock defines a well-characterized patient subset; however, subgroup analysis, even in a well-defined subpopulation, has the potential for selection bias and sampling error. It is plausible that data exploration in ALBIOS to identify a subgroup with a positive treatment effect resulted in an overestimation of albumin’s potential effect. Moreover, subgroup analysis (prespecified or post hoc) can lead to conclusions of false benefit arising from multiple testing. It would certainly not be the first time that biologically plausible treatments fail to show benefit when tested in critically ill patients. A study on albumin replacement in patients with septic shock found no significant mortality difference.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543